An evaluation of the cardiotoxicity of imatinib mesylate.
We studied 103 consecutive patients with chronic myeloid leukaemia on treatment with imatinib (IM) and 57 patients with chronic myeloproliferative disorders not treated with IM in order to evaluate its cardiotoxicity. There was no statistical difference regarding cardiac symptoms and signs, BNP levels and echocardiographic measurements for IM and control groups, except for peripheral oedema, more frequent in the IM group. Four patients in the IM group presented a BNP level >100pg/ml, one of them with depressed LVEF. IM was not related to systematic deterioration of cardiac function, but there is still a possibility of isolated cases of cardiotoxicity.
Ribeiro
Antonio Luiz
AL
School of Medicine, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. tom@hc.ufmg.br
Marcolino
Milena Soriano
MS
Bittencourt
Henrique N S
HN
Barbosa
Márcia M
MM
Nunes
Maria do Carmo P
Mdo C
Xavier
Vitor Fonseca
VF
Clementino
Nelma C D
NC
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000503:physiopathology; D016279:Atrial Function, Left / Q000187:drug effects; D016280:Atrial Function, Right / Q000187:drug effects; D001549:Benzamides; D001794:Blood Pressure / Q000187:drug effects; D054715:Cardiotoxins / Q000633:toxicity*; D004562:Electrocardiography / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use* / Q000633:toxicity*; D011743:Pyrimidines / Q000627:therapeutic use* / Q000633:toxicity*
D000970:Antineoplastic Agents; D001549:Benzamides; D054715:Cardiotoxins; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate